Literature DB >> 28669449

Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.

H Cain1, I R Macpherson2, M Beresford3, S E Pinder4, J Pong5, J M Dixon6.   

Abstract

Neoadjuvant treatment offers a number of benefits for patients with early breast cancer, and is an important option for consideration by multidisciplinary teams. Despite literature showing its efficacy, the use of neoadjuvant therapy varies widely. Here we discuss the clinical evidence supporting the use of neoadjuvant therapy in early stage breast cancer, including patient selection, monitoring response, surgery and radiotherapy considerations, with the aim of assisting multidisciplinary teams to determine patient suitability for neoadjuvant treatment.
Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; chemotherapy; endocrine therapy; multidisciplinary; neoadjuvant treatment; patient management

Mesh：

Year:  2017        PMID： 28669449     DOI： 10.1016/j.clon.2017.06.003

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  29 in total

1.  Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Authors:  Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; Ann Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary W Unzeitig; Melanie E Royce; Kelly K Hunt
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

Review 2.  Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis.

Authors:  Kristen Mcalpine; Dean A Fergusson; Rodney H Breau; Luke F Reynolds; Risa Shorr; Scott C Morgan; Libni Eapen; Ilias Cagiannos; Chris Morash; Luke T Lavallée
Journal:  Can Urol Assoc J       Date:  2018-05-28       Impact factor: 1.862

3.  A retrospective review of MRI features associated with metastasis-free survival in women with breast cancer: focusing on skin thickening and skin enhancement.

Authors:  Valentine Mberu; Jennifer McFarlane; E Jane Macaskill; Andrew Evans
Journal:  Br J Radiol       Date:  2021-10-05       Impact factor: 3.039

4.  Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy.

Authors:  Raffaella Massafra; Maria Colomba Comes; Samantha Bove; Vittorio Didonna; Gianluca Gatta; Francesco Giotta; Annarita Fanizzi; Daniele La Forgia; Agnese Latorre; Maria Irene Pastena; Domenico Pomarico; Lucia Rinaldi; Pasquale Tamborra; Alfredo Zito; Vito Lorusso; Angelo Virgilio Paradiso
Journal:  J Pers Med       Date:  2022-06-10

5.  NEOADJUVANT LENVATINIB IN ADVANCED UNRESECTABLE MEDULLARY THYROID CARCINOMA: A CASE REPORT.

Authors:  Hubert Golingan; Brian Hunis; Allan C Golding; David N Bimston; R Mack Harrell
Journal:  AACE Clin Case Rep       Date:  2019-12-20

6.  Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.

Authors:  Qing Liu; Johnie Hodge; Junfeng Wang; Yuzhen Wang; Lianming Wang; Udai Singh; Yong Li; Yongzhong Yao; Dawei Wang; Walden Ai; Prakash Nagarkatti; Hexin Chen; Peisheng Xu; E Angela Murphy; Daping Fan
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

7.  Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs.

Authors:  Maria Colomba Comes; Annarita Fanizzi; Samantha Bove; Vittorio Didonna; Sergio Diotaiuti; Daniele La Forgia; Agnese Latorre; Eugenio Martinelli; Arianna Mencattini; Annalisa Nardone; Angelo Virgilio Paradiso; Cosmo Maurizio Ressa; Pasquale Tamborra; Vito Lorusso; Raffaella Massafra
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

8.  Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.

Authors:  Koichi Kubouchi; Kyosuke Shimada; Takamichi Yokoe; Yutaka Tsutsumi
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer - A randomized controlled trial.

Authors:  Maria Fjell; Ann Langius-Eklöf; Marie Nilsson; Yvonne Wengström; Kay Sundberg
Journal:  Breast       Date:  2020-03-20       Impact factor: 4.380

10.  Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience.

Authors:  Katalin Boér; Zsuzsanna Kahán; László Landherr; Tibor Csőszi; Károly Máhr; Ágnes Ruzsa; Zsolt Horváth; Barna Budai; Gábor Rubovszky
Journal:  Pathol Oncol Res       Date:  2021-05-04       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.